84 results about "Antiplatelet drug" patented technology

A method for obtaining a percent aggregation or inhibition of platelets resulting from anti-platelet using a single blood sample is achieved. An assay device is provided. The assay device has multiple channels, each coupled to a common introduction port. A first platelet activator is sensitive to activation pathway targeted by the anti-platelet drug. A second platelet activator is insensitive to the activation pathway targeted by the anti-platelet drug. An anti-coagulated sample is introduced simultaneously to the first and second channels. A level of platelet aggregation is simultaneously made in both channels.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and(b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.

Disclosed is an antithrombotic neurovascular device useful for the treatment of brain aneurysms and / or acute ischemic stroke. The device comprises a mechanical structure, which may be a stent, stent-like structure, or flow diverter, and a drug-eluting coating. This device is designed for local delivery of antiplatelet medication to the site of device implantation in order to improve outcomes for the population of brain aneurysm and / or acute ischemic stroke patients currently being treated with stents, and for use with patients presenting with ruptured aneurysms, in whom systemic dual antiplatelet therapy is contraindicated. The coating comprises an antiplatelet drug, preferably, a GPIIb / IIIa receptor inhibitor, more preferably, abcixmab, and optionally comprises a polymeric binder that functions as a drug modulating polymer. Also disclosed are methods for producing the antithrombotic neurovascular device, and using the device for the treatment of brain aneurysms and / or acute ischemic stroke.

The present invention provides dextral indobufen or acceptable salt in pharmacy, which has a structure as shown in formula I. The compound can be used as an anti-platelet drug.

The invention, belonging to the technical field of medicine, relates to a bi-functional anti-platelet aggregation medicine and an application of the medicine in preventing and treating arterial tlirombotic diseases. The medicine of the invention has both a P2Y12 receptor antagonist property and a phosphodiesterase inhibitory activity. The results of in vivo and in vitro anti-platelet aggregation activity experiments of the medicine provide the anti-platelet mechanism of the medicine, the structural formula and anti-platelet mechanism of the medicine are different from those of known anti-platelet medicines, aspirin, Clopidogrel, Prasugrel, Cilostazol, and platelet and fibrinogen receptor antagonist. The medicine of the invention has good inhibition effect to various platelet aggregation induced by agonists. The results of mice in vivo experiment models of arterial thrombosis show that the medicine of the invention has significantly similar antithrombotic activity with Clopidogrel and non-obvious side effect of hemorrhage. The medicine of the invention can be used as antithrombotic medications for treating coronary heart disease, apoplexy and other arterial tlirombotic diseases.

The invention relates to a prasugrel pamoate salt and a preparation method thereof. The prasugrel pamoate salt has a structure represented by the formula II, and has the advantages of good stability, low hygroscopicity, and high safety. Moreover, the preparation method has the advantages of simple operation and good repeatability. The provided prasugrel salt can be used as an anti-platelet drug.

A slide fastener bioabsorbable stent is applied as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent includes a snap fastener stent, an edge slide fastener stent, a middle slide fastener stent, and a double fastener stent. The slide fastener bioabsorbable stent has good degradability and biocompatibility, and is more suitably used as a pediatric vascular stent, with which no late-onset stent thromboses after implanted, and thus it is not necessary to long-term take antiplatelet drugs and the subsequent surgical operation may not be affected. Also, it has a strong support, and thus can be widely used as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent has simple production and convenient drug carrying, which can be used as a carrier of medicine or gene treatment. The stent can be matched with a delivery system, hence the difficulty of the surgery operation is reduced. Many animal experiments show that slide fastener bioabsorbable stent has high success ratio when being used, and has apparent curative effect and good clinical application prospect.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

The invention discloses an application of tannic acid in preparation of antithrombotic drugs and particularly drugs for inhibiting platelet activation / aggregation. According to in-vitro and animal studies, the natural compound tannic acid can obviously inhibit the platelet phospholipid splicing, activation and aggregation at low concentration and shows remarkable anti-platelet and antithrombotic effects without increasing the risk of bleeding; the tannic acid can be extracted from plants or synthesized industrially, and the production cost is low; and moreover, the tannic acid, developed as a novel anti-platelet drug, has broad application prospects and huge market potential and social values.

The invention discloses application of substituted pyrimidine molecule modified gold nanoparticles in preparing anticoagulants or antiplatelet drugs. The substituted pyrimidine molecule for modifying the gold nanoparticles is one or a mixture of at least two of 2-thiol-4,6-diaminopyrimidine, 2-thiol-4-aminopyrimidine and 2-thiol-4,6-dihydroxylpyrimidine. According to the gold nanoparticles, the substituted pyrimidine part without anticoagulant activity is connected with gold nanoparticles without anticoagulant activity through an S-Au bond to be applied to the anticoagulation field for the first time; the substituted pyrimidine molecule modified gold nanoparticles obtain unexpected anticoagulation effect, the preparation method is simple, the nanoparticles are small in diameter distribution and can be well dispersed in water, cannot cause bleeding side effect in normal dosage, and can be used for preparing anticoagulants or antiplatelet drugs.

The present invention relates to an immunologic mechanism for gastrointestinal diseases such as non-infectious gastrointestinal diseases including child non-infectious gastrointestinal diseases, and anovel application of a phosphodiesterase inhibitor and / or an antiplatelet drug to treatment of the gastrointestinal diseases such as the non-infectious gastrointestinal diseases.

The invention belongs to the technical field of antiplatelet drugs and provides 1,4-disubstituted piperazine derivatives and pharmaceutically acceptable salts thereof. The 1,4-disubstituted piperazine derivatives have a general structural formula I. In the general structural formula I, x, y, m, R1, R2, R3 and R4 are defined in the patent specification. The invention relates to a preparation method of the 1,4-disubstituted piperazine derivatives, discloses a drug composition containing the 1,4-disubstituted piperazine derivatives or their pharmaceutically acceptable salts as active ingredients, and also discloses a use of the 1,4-disubstituted piperazine derivatives and their pharmaceutically acceptable salts in antiplatelet drugs.

The invention relates to a method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx, relating to a drug extracting method, which comprises the following steps of crushing dried Chinese lantern-plant stems and persistent calyx, then extracting for 1-5 times and 5-15 min with the microwave radiation power of 380-680 W and 60-90% ethanol, wherein the material-to-liquid ratio is 1:10 to 1:40; after extracting, filtering, extracting, mixing extraction solutions to prepare an extract; after the extract is dissolved, measuring through a vanillic aldehyde-perchloric acid colorimetric method based on dioscin as the standard substance to calculate the content of saponin in the extract. By means of the microwave extraction method, the extraction time can be obviously shortened; the yield of steroid saponin is increased; the medicinal and edible dual-purpose resources of steroid saponin in the Chinese lantern-plant stems can be sufficiently utilized; in addition, after being separated and purified, steroid saponin in Chinese lantern-plant stems and persistent calyx extracted through the method disclosed by the invention can be used for preparing the drugs, such as antibacterial drugs, expectorant drugs, antiplatelet drugs, lipid-lowering drugs and anti-tumour drugs, or used as the raw material of functional foods and health-care foods.

The invention discloses a COX-1 gene polymorphism site related to aspirin resistance and application. Antiplatelet drugs (especially aspirin) play a crucial role in preventing and curing the ischemic stroke, however, current survey results show that even if many ischemic stroke patients have taken the antiplatelet drugs, the stroke still reoccurs repeatedly, and the phenomenon is called antiplatelet drug resistance. An applicant defines one COX-1 gene polymorphism site COX-1(A842G) related to aspirin resistance, and designs a primer detecting site polymorphism for the site, and the primer can be used for preparing kits screening the aspirin resistance patients so as to select the antiplatelet drugs for the ischemic stroke patients and reduce aspirin resistance and the stroke reoccurrence rate.

The invention relates to an application of a novel slide buckle bio-absorbable stent in manufacture of a cardiovascular system or a lumen stent for cardiovascular or luminal stenosis diseases. The application has the advantages as follows: the novel slide buckle bio-absorbable stent has good degradability and biocompatibility and is applicable to pediatric intravascular stents, and late stent thrombosis cannot occur after implantation, so that antiplatelet drugs are not required to be taken for a long time, and possible subsequent surgical operations cannot be affected; the support force is high, the novel slide buckle bio-absorbable stent can be taken as a cardiovascular system stent or a lumen stent and can be widely applied in the cardiovascular or luminal stenosis diseases; the manufacture is simple and convenient, medicine carrying is facilitated, and the stent can be used as a drug or gene therapy carrier; the stent is equipped with a delivery system at the same time, and the operation difficulty is reduced; and a large number of animal experiments show that the novel slide buckle bio-absorbable stent has a higher success rate during the usage, the curative effect is remarkable, and the stent has a better clinical application prospect.

The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I:wherein,X is N, or CR1d,Xb1-Xb5 are the same or different, and are nitrogen or carbon,R1a-R1d are the same or different, and are hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted alkylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino,R2 is an optionally substituted aryl or an optionally substituted heteroaryl,R3 is an optionally substituted aryl or an optionally substituted heteroaryl, orpharmaceutically acceptable salt thereof as an active ingredient.

The invention discloses an encephalic drug eluting stent in the field of medicines, and particularly relates to the drug eluting stent used for curing the encephalic atherosclerotic stenosis disease. Diseased blood vessels are expanded by the stent to improve the condition of stenosis, so as to improve the blood flow state, meanwhile, drug carried by the stent can be used for preventing a tunica elastica interna from hyperplasia, and the probability of in-stent restenosis can be lowered. The encephalic drug eluting stent comprises a conveying system, a stent body and a stent drug carrying layer, and is characterized in that one or more drug carrying layers are attached to the surface of the encephalic drug eluting stent; each drug carrying layer is composed of a polymer and an active ingredient, the active ingredient is an antiplatelet drug cilostazol, and each drug carrying layer comprises the following components by weight percent: 5 to 50 percent of the polymer and the balance of active ingredients; the active ingredients in all medicine carrying layers are the same or different. The encephalic drug eluting stent provided by the invention has the advantages that the functions of protecting blood vessels, restraining inflammation reactions, expanding blood vessels and the like can be achieved, and the purpose of preventing encephalic vascular in-stent restenosis can be achieved.

The invention relates to a drug eluting balloon. The drug eluting balloon comprises a balloon body, wherein the middle of the balloon body is cylindrical, the two ends of the balloon body are conical, one end of the balloon body is connected with a connecting pipe through a guide pipe, a plurality of pits are formed in the outer wall of the cylindrical middle portion of the balloon body, the elasticity modulus of each pit is smaller than the elasticity modulus of the balloon body, the elasticity modulus difference meets the conditions that the pits sink towards the interior of the balloon body when the balloon body is filled with no filing medium and the pits protrude towards the outside of the balloon body when the balloon body is filled with filling media, and by the adoption of the design, the superficial area of the balloon is increased, drug adhesion is improved, drugs are ejected in the form of a drug pill when the balloon expands, and it is guaranteed that drugs are released fully in a short time. According to the drug eluting balloon, a special structure is adopted, the drug loading capacity is improved based on a traditional drug balloon, and drugs are released fully through ejection; after the drug balloon is used, the defects of a drug support can be effectively overcome, a patient just needs to take duplex antiplatelet drugs conventionally in a short time, and the metal burden and the economical burden of the patient are greatly reduced.

The invention relates to a kit for detecting an antiplatelet drug in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The pretreatment processis simple, the cost is low, the sensitivity is high, the specificity is high, separation and detection of the antiplatelet drug are completed within 5 min, the accuracy and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antiplatelet drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antiplatelet drug.

The present invention discloses a valve with anti-thrombosis and anti-calcification functions, and a preparation method and an application of the valve. The valve comprises a valve base and a zwitterionic copolymer covalently connected to the valve base. During preparation, the valve base is firstly soaked in a glutaraldehyde solution to obtain a cross-linked valve; and then the cross-linked valveis soaked in a zwitterionic polymer solution with a concentration of 0.1-5 wt% for reaction for 2-4 days, and then reduction with a reducing agent is conducted to obtain the valve with the anti-thrombosis and anti-calcification functions. The valve material is subjected to anti-thrombosis and anti-calcification treatments, so that after the valve is implanted in patients, risks of valve leaflet thrombosis can be reduced, valve leaflet thickening and transvalvular differential pressure increase are prevented, a long-term hydrodynamic performance is improved, patients can avoid or reduce uses of anticoagulant and antiplatelet drugs, risks of patient bleeding are reduced, besides, aldehyde residues in the valve leaflet tissues are reduced, biocompatibility and anti-calcification ability areimproved, and ultimately complications of valve leaflet thrombosis are reduced and service life of the valve is extended.

The invention relates to a method for detecting an antiplatelet drug in blood plasma by using an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The method has the advantages that the pretreatment process is simple, the cost is low, the sensitivity is high, the specificity is high, separation and detection of the antiplatelet drug are completed within 5 min, the accuracy degree and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antiplatelet drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antiplatelet drug.

The invention discloses a SNP marker relevant with treatment of ischemic stroke through antiplatelet drug clopidogrel and application thereof, as well as a special amplification primer and a special extension primer for detecting the marker. The SNP marker is combination of rs6686001, rs2302429, rs2242480, rs4244285 and rs2046934. Sequences of each marker, the special amplification primer and the special extension primer are sequentially respectively as shown in SEQ ID No. 1-20. According to the SNP marker combination, clopidogrel-resistant and clopidogrel-effective ischemic stroke people can be distinguished well. The SNP marker, the amplification primer thereof and a relevant kit can be used for clinical medication guidance for adopting the antiplatelet drug clopidogrel to treat ischemic stroke patients, medicine resistance is prevented, and a treatment effect is enhanced.

The invention relates to the technical field of medical examination, and specially relates to a method for simultaneous determining concentrations of ticagrelor and active metabolites and endogenous adenosine thereof in human plasma by liquid chromatography-mass spectrometry. The concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma are simultaneously determined by adopting a liquid chromatography-mass spectrometry technology. The method comprises the following steps: A, simultaneously determining the concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma; B, all the samples to be detected can be subjected to peak determination under the same chromatographic and mass spectrometric conditions;and C, simultaneously extracting to-be-detected substances with different polarities in the sample. The method has the advantages that the adenosine concentration change in the blood plasma in the body of the patient and the relationship between the adenosine concentration change and the concentration of the ticagrelor and the active metabolite thereof in the blood plasma after the antiplatelet drug ticagrelor is taken can be accurately, simply, conveniently and quickly evaluated. In addition, pretreatment and chromatographic and mass spectrometric conditions are optimized, so that the determination method is simple, quick and sensitive to operate, high in specificity and good in repeatability.

The invention belongs to the technical field of biology, and particularly to a molecular marker for diagnosis of diabetes and application thereof. For the problem that currently, no reliable biomarkercan perform risk prediction and early diagnosis on the diabetes, the following solution is proposed that the molecular marker comprises a kit and diagnostic primers, wherein the kit is internally provided with a chip, the chip comprises a gene chip, a gene primer and a molecular marker, the diagnostic primers comprise the forward primer and the reverse primer, and the forward primer and the reverse primer are both set to have RNA molecule sequences. Trough the detection of items related to a thrombus molecular marker, not only is further knowing of complications of DM vascular injuries and the pathogenesis of thrombosis facilitated, but also a basis is provided for using anticoagulant antiplatelet drugs for treatment, and the detection of molecules of type 2 diabetes patients has important clinical significance for the early prevention or intervention of thrombogenesis and vasculopathy.

A blood state analysis device (1) that analyzes a state of a blood sample, as used for clotting time testing, said blood sample comprising a plasma and at least one reagent, including a correction unit (11) configured to correct a measured blood coagulation evaluation result of the blood sample based on a relation between reference concentrations of the at least one reagent in plasma and reference blood coagulation evaluation results, the at least one reagent is an anticoagulation treatment releasing agent, a coagulation activator, an anticoagulant, a platelet activator, an antiplatelet drug, or a combination thereof and is present in the blood sample. For instance, such device (1) allows to correct blood clotting time results with respect to concentrations of an anti-coagulant drug present in the blood sample.

The present invention provides tests that measures functional platelet aggregation such as by using Light Transmission Aggregometry Assays (LTAAs) or flow cytometry, using synthetic, self-assembling human type I collagen, methods of predicting and measuring an individual's platelet anti-platelet medication sensitivity and residual platelet activity status when the individual is on a dual anti-platelet therapy of aspirin and anti-platelet medication and kits useful in the assays and methods.